Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …

Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

Tolerance to self-antigens prevents the elimination of cancer by the immune system,. We
used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and …

Summary Lymphocyte-activation gene 3 (LAG-3) is an immune inhibitory receptor, with
major histocompatibility complex class II (MHC-II) as a canonical ligand. However, it remains …

The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …

LAG3 is an inhibitory receptor that is highly expressed on exhausted T cells. Although LAG3-
targeting immunotherapeutics are currently in clinical trials, how LAG3 inhibits T cell function …

LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal,
or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial - PMC Back to Top …

Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T
cell responses and have proven to be effective targets in the setting of chronic diseases …